Xencor, Inc Depreciation
Xencor, Inc (XNCR) reported Depreciation of $712.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2017-03-01
- Xencor, Inc depreciation for fiscal 2016 was $712.00K, a 37.19% increase from fiscal 2015.
- Xencor, Inc depreciation for fiscal 2015 was $519.00K, a 176.06% increase from fiscal 2014.
- Xencor, Inc depreciation for fiscal 2014 was $188.00K, a 66.37% increase from fiscal 2013.
- Xencor, Inc depreciation for fiscal 2013 was $113.00K, a 26.62% decline from fiscal 2012.
| Period end | Depreciation 12 month |
|---|---|
| 2016-12-31 | $712.00K 10-K · filed 2017-03-01 |
| 2015-12-31 | $519.00K 10-K · filed 2017-03-01 |
| 2014-12-31 | $188.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | $113.00K 10-K · filed 2016-03-08 |
| 2012-12-31 | $154.00K 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |